India Pharma Exports Rise 6.8% to $8.1B; US Buys $2.5B in Q1 FY27

For investors, the $8.1B quarter is a story of quality beneath the headline: a 6.8% overall gain is being driven by 35.68% vaccine growth and 13.84% bulk drug growth, while the $5.98B formulations base — 73.85% of revenue — grows just 4.14%. That mix, plus a 30.89% US concentration, defines both the bull and bear cases for Indian pharma exposure.

India's pharmaceutical exports climbed 6.8% year-on-year to $8.10 billion in the first quarter of fiscal year 2027 (April–June 2026), up from $7.58 billion a year earlier, according to data released by the Pharmaceuticals Export Promotion Council of India (Pharmexcil) on August 12, 2026. The headline number, however, conceals a meaningful rotation inside India's export basket. Vaccine shipments surged 35.68% to $390 million, bulk drugs and drug intermediates grew 13.84% to $1.36 billion, and surgical products rose 11.95% to $210 million — while drug formulations and biologicals, still the dominant category at $5.98 billion or 73.85% of total exports, expanded a comparatively modest 4.14% year-on-year.

“

For investors, the $8.1B quarter is a story of quality beneath the headline: a 6.8% overall gain is being driven by 35.68% vaccine growth and 13.84% bulk drug growth, while the $5.98B formulations base — 73.85% of revenue — grows just 4.14%.

The monthly trajectory supports the view that momentum is building rather than plateauing. June exports rose 7.13% year-on-year to $2.81 billion, up 6.86% from $2.63 billion in May of the current fiscal year. That sequential gain, stacked on top of the quarterly increase, indicates Indian pharma is compounding from an already high base rather than merely lapping easy comparisons.

Geographically, the data shows breadth with concentration at the top. North America, Europe, Africa and Latin America and the Caribbean together accounted for nearly 75% of India's pharmaceutical exports during the quarter. North America alone held a 34.28% regional share, and the United States remained the largest single destination at $2.50 billion, or a 30.89% share, followed by Brazil, the United Kingdom, the Netherlands and France. The top 25 export destinations together absorbed $5.65 billion — roughly 70% of the total — and grew 5.50% year-on-year, confirming that India's export growth is distributed across a wide set of buyers even as the US dominates.

Pharmexcil struck a cautiously optimistic tone, noting that continued product diversification, regulatory compliance and expansion into new markets will be important to maintain momentum. That framing matters because it implicitly acknowledges the structural challenge: the formulations segment, which still accounts for nearly three-quarters of export value, is growing at roughly one-third the pace of the overall basket, while the faster-growing vaccine, bulk drug and surgical segments remain comparatively small.

For the industry, the numbers point to a deliberate shift toward higher-value, faster-growing categories. Vaccines' 35.68% growth — more than eight times the rate of the formulations segment — reflects India's deepening capability in biologics and its expanding cold-chain and regulatory infrastructure, positioning the country as a reliable supplier of complex, temperature-sensitive products to both developed and emerging markets. The 13.84% growth in bulk drugs and drug intermediates is equally significant as a signal of India's active pharmaceutical ingredient self-reliance agenda, reinforced by production-linked incentive schemes aimed at reducing dependence on China for key starting materials.